Clinical trials in Chaidari – page 73

1 008 clinical trials in Chaidari, Greece across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GreeceΚλινικεσΔοκιμεσ.gr

Chaidari at a glance

1 008

clinical trials

Research sites1

Quick filters

1 008 trials in Chaidari

Open in trial search

Plasma cell myeloma+13

Not recruiting

Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials

Registered drugNo placebo

Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Alectinib
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Asthma

Not recruiting

Study on the Long-term Effects of Dupilumab in Preventing Lung Function Decline in Adults with Uncontrolled Moderate to Severe Asthma

Investigational

Study on the Long-term Effects of Dupilumab in Preventing Lung Function Decline in Adults with Uncontrolled Moderate to Severe Asthma

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:Dupilumab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Dry eye+1

Not recruiting

Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

Registered drug

Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Ianalumab
Sponsor:Novartis Pharma AG

Contact Research Centre

Arteriovenous graft thrombosis

Not recruiting

Study on MK-2060 for Preventing Blood Clots in Dialysis Patients with End-Stage Kidney Disease

Investigational

Study on MK-2060 for Preventing Blood Clots in Dialysis Patients with End-Stage Kidney Disease

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:MK-2060
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Non-small cell lung cancer stage III

Not recruiting

Study of Atezolizumab and Tiragolumab Compared to Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo

Study of Atezolizumab and Tiragolumab Compared to Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

HER2 positive breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Trastuzumab Deruxtecan
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Breast cancer

Not recruiting

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Registered drug

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Alpelisib
Sponsor:Novartis Pharma AG

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study Comparing Adagrasib and Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo

Study Comparing Adagrasib and Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Adagrasib
Sponsor:Mirati Therapeutics Inc.

Contact Research Centre

Thrombotic thrombocytopenic purpura

Not recruiting

Study on Caplacizumab and Immunosuppressive Therapy for Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Registered drugNo placebo

Study on Caplacizumab and Immunosuppressive Therapy for Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Caplacizumab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Adrenogenital syndrome

Not recruiting

Study on the Safety and Effectiveness of Crinecerfont for Adults with Classic Congenital Adrenal Hyperplasia

Investigational

Study on the Safety and Effectiveness of Crinecerfont for Adults with Classic Congenital Adrenal Hyperplasia

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:Crinecerfont
Sponsor:Neurocrine Biosciences Inc.

Contact Research Centre

Glycogen storage disease type II

Not recruiting

Study on Long-term Safety and Efficacy of Cipaglucosidase Alfa and Miglustat for Adults with Late-onset Pompe Disease

InvestigationalNo placebo

Study on Long-term Safety and Efficacy of Cipaglucosidase Alfa and Miglustat for Adults with Late-onset Pompe Disease

InvestigationalNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Miglustat
Sponsor:Amicus Therapeutics Inc.

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study of Durbactagene Autoleucel and Drug Combination for Adults with Relapsed and Refractory Multiple Myeloma

Registered drugNo placebo

Study of Durbactagene Autoleucel and Drug Combination for Adults with Relapsed and Refractory Multiple Myeloma

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Bendamustine
Sponsor:Novartis Pharma AG

Contact Research Centre

Other cities in Greece

The busiest research cities in the country

All 45 cities in Greece

Clinical research in Chaidari

What the registry says about research in the country

01 Head and Neck Cancer Research

Innovative clinical research focusing on squamous cell carcinoma of the head and neck, exploring combination therapy approaches that integrate immunotherapy with traditional treatments.

Immunotherapy Integration
Combination Treatment Strategies
Post-Surgery Care

The study evaluates the effectiveness of combining nivolumab with standard cisplatin-radiotherapy, aiming to improve disease-free survival rates in patients with resected head and neck cancer.

Back to Greece All countries